Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-25

Clinical Trial Update: Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 trial of Volixibat (SHP626) in adults with nonalcoholic steatohepatitis was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Volixibat (volixibat)

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Non-Alcoholic Steatohepatitis | Phase 2 | Status: TERMINATED | Results posted: 2019-11-25